Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Blueprint Medicines Corporation - Common Stock
(NQ:
BPMC
)
129.46
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Blueprint Medicines Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
3 Biotech Stocks Using AI to Change Healthcare Forever
↗
July 14, 2023
These three biotech firms are leveraging artificial intelligence to revolutionize therapeutics and make disease a thing of the past.
Via
InvestorPlace
Analyst Ratings for Blueprint Medicines
↗
July 14, 2023
Via
Benzinga
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
↗
July 01, 2023
Via
Talk Markets
ETF Returns: Mid-Cap Winners And Losers
↗
June 28, 2023
We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on...
Via
Benzinga
What Will AbbVie Buy Next?
↗
June 28, 2023
Two mid-cap drugmakers stand out as logical targets for AbbVie.
Via
The Motley Fool
Analyst Expectations for Blueprint Medicines's Future
↗
June 14, 2023
Via
Benzinga
FDA OKs Blueprint Medicines' Blood Disorder Drug As First Treatment For SM Patients
↗
May 23, 2023
The U.S.
Via
Benzinga
Analyst Expectations for Blueprint Medicines's Future
↗
May 23, 2023
Via
Benzinga
Blueprint Medicines's Return On Capital Employed Overview
↗
May 15, 2023
Via
Benzinga
3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon
↗
June 12, 2023
These three small cap drug companies could become gold or lead depending on the outcomes of their clinical trials.
Via
InvestorPlace
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
June 05, 2023
Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.
Via
Benzinga
EPAM Systems, Amyris, Blueprint Medicines And Other Big Stocks Moving Lower On Monday
↗
June 05, 2023
U.S. stocks traded mixed, with the Dow Jones dropping around 100 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Analyst Ratings for Blueprint Medicines
↗
May 05, 2023
Via
Benzinga
Where Blueprint Medicines Stands With Analysts
↗
April 19, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 5, 2023
↗
June 05, 2023
Via
Benzinga
US Stocks Mixed; SAIC Posts Upbeat Results
↗
June 05, 2023
U.S. stocks traded mixed this morning, with Dow Jones dropping around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.06% to 33,740.98 while the NASDAQ rose 0.08% to...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
June 05, 2023
Via
Benzinga
Meta Platforms To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Monday
↗
June 05, 2023
BMO Capital boosted the price target for Equity Residential (NYSE: EQR) from $60 to $64. BMO Capital analyst John Kim upgraded the stock from Underperform to Market Perform. Equity Residential shares...
Via
Benzinga
16 Analysts Have This to Say About Blueprint Medicines
↗
March 30, 2023
Via
Benzinga
FDA Removes Partial Clinical Hold From Blueprint Medicines' Cancer Study
↗
March 29, 2023
Via
Benzinga
This Biotech Could Soon Go Parabolic, But Should You Buy It?
↗
June 04, 2023
Its situation is neither as good nor as bad as it might seem at first glance.
Via
The Motley Fool
Blueprint Medicines Earns Higher Price Targets Post FDA Approval: Analysts Optimistic on Ayvakit's Future
↗
May 23, 2023
Shares of Blueprint Medicines Corporation (NASDAQ: BPMC) after it received FDA approval for its Ayvakit (avapritinib) as the first, only treatment for
Via
Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
↗
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Where Blueprint Medicines Stands With Analysts
↗
February 27, 2023
Via
Benzinga
Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients
↗
February 27, 2023
Via
Benzinga
Earnings Scheduled For February 16, 2023
↗
February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...
Via
Benzinga
Earnings Preview For Blueprint Medicines
↗
February 15, 2023
Via
Benzinga
Analyst Ratings for Blueprint Medicines
↗
January 23, 2023
Via
Benzinga
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
↗
February 23, 2023
Via
Benzinga
FDA Slaps Partial Clinical Hold On Blueprint Medicines' Early-Stage Solid Tumor Study
↗
February 10, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today